Silence Therapeutics presented what seemed like positive data on zerlasiran, its experimental drug for reducing cardiovascular risk. Then, its stock fell 36%. What happened?
Investors tell Silence Therapeutics to shush
view original post
Silence Therapeutics presented what seemed like positive data on zerlasiran, its experimental drug for reducing cardiovascular risk. Then, its stock fell 36%. What happened?